Source: http://www.google.com/patents/US8057792?dq=7,403,220
Timestamp: 2015-08-01 12:08:38
Document Index: 782915197

Matched Legal Cases: ['art 10', 'art 13', 'art 5', 'art 6', 'art 7', 'art 8', 'art 9', 'Application No. 2', 'Application No. 07009705', 'Application No. 2000']

Patent US8057792 - Use of an antibody that blocks TNF-alpha activity for treating a nerve ... - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inAdvanced Patent SearchPatentsThe present invention relates to a method and a pharmaceutical composition for treatment of nerve disorders comprising administration of a therapeutically effective dosage of at least two substances selected from the group consisting of TNF inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors,...http://www.google.com/patents/US8057792?utm_source=gb-gplus-sharePatent US8057792 - Use of an antibody that blocks TNF-alpha activity for treating a nerve disorder mediated by nucleus pulposusAdvanced Patent SearchPublication numberUS8057792 B2Publication typeGrantApplication numberUS 12/714,708Publication dateNov 15, 2011Filing dateMar 1, 2010Priority dateSep 25, 1998Also published asUS7115557, US7708995, US20030039651, US20070104711, US20100150922, US20120093816, US20120244157Publication number12714708, 714708, US 8057792 B2, US 8057792B2, US-B2-8057792, US8057792 B2, US8057792B2InventorsKjell Olmarker, Bjorn RydevikOriginal AssigneeSciaticon AbExport CitationBiBTeX, EndNote, RefManPatent Citations (99), Non-Patent Citations (253), Classifications (46), Legal Events (2) External Links: USPTO, USPTO Assignment, EspacenetUse of an antibody that blocks TNF-alpha activity for treating a nerve disorder mediated by nucleus pulposus
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS4666897Dec 29, 1983May 19, 1987Research Foundation Of State UniversityInhibition of mammalian collagenolytic enzymes by tetracyclinesUS4925833Dec 29, 1986May 15, 1990The Research Foundation Of State University Of New YorkUse of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosisUS5304633Sep 5, 1991Apr 19, 1994Morinaga Milk Industry Co., Ltd.Fragments of lactoferrin having potent antimicrobial activityUS5395760May 10, 1990Mar 7, 1995Immunex CorporationDNA encoding tumor necrosis factor-α and -β receptorsUS5565272Jul 10, 1992Oct 15, 1996Nippon Steel CorporationGrain oriented silicon steel sheet having excellent primary film propertiesUS5565425Mar 2, 1994Oct 15, 1996Snow Brand Milk Products Co., LtdViral infection and proliferation inhibitorsUS5574022Apr 14, 1994Nov 12, 1996The Center For Innovative TechnologyMethod of attenuating physical damage to the spinal cordUS5602157May 18, 1995Feb 11, 1997Smithkline Beecham CorporationCompounds useful for treating allergic and inflammatory diseasesUS5605690Feb 8, 1995Feb 25, 1997Immunex CorporationMethods of lowering active TNF-α levels in mammals using tumor necrosis factor receptorUS5643915Jun 6, 1995Jul 1, 1997Andrulis Pharmaceuticals Corp.Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapiesUS5650396Mar 15, 1994Jul 22, 1997Celtrix Pharmaceuticals, Inc.Methods of modulating inflammatory cytokines in the CNS using TGF-βUS5656272Feb 4, 1994Aug 12, 1997New York University Medical CenterMethods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodiesUS5672347May 5, 1995Sep 30, 1997Genentech, Inc.Tumor necrosis factor antagonists and their useUS5686428Feb 4, 1994Nov 11, 1997Aktiebolaget AstraPharmaceutical compositionUS5698195Oct 18, 1994Dec 16, 1997New York University Medical CenterMethods of treating rheumatoid arthritis using chimeric anti-TNF antibodiesUS5703092Apr 16, 1996Dec 30, 1997The Dupont Merck Pharmaceutical CompanyHydroxamic acid compounds as metalloprotease and TNF inhibitorsUS5756482May 16, 1996May 26, 1998The Center For Innovative TechnologyMethod of attenuation of nervous system damageUS5763446Mar 26, 1992Jun 9, 1998University Of Southern CaliforniaUse of pentoxifylline and other tumor necrosis factor blockers for the treatment of aids-associated optic neuropathy and other central nervous system diseasesUS5795967Jun 7, 1995Aug 18, 1998Genentech, Inc.Tumor necrosis factor antagonists and their useUS5919452Feb 4, 1994Jul 6, 1999New York UniversityMethods of treating TNFα-mediated disease using chimeric anti-TNF antibodiesUS5945397May 16, 1996Aug 31, 1999Immunex CorporationPurified p75 (type II) tumor necrosis factor receptor polypeptidesUS5962481Oct 6, 1997Oct 5, 1999American Cyanamid CompanyPreparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitorsUS6001828Oct 23, 1997Dec 14, 1999Andrulis, Jr.; PeterUse of tumor factor inhibitors together with antiviral agents and therapeutic compositions thereof against HIV infectionUS6015557Mar 23, 1999Jan 18, 2000Tobinick; Edward L.Tumor necrosis factor antagonists for the treatment of neurological disordersUS6177077Dec 31, 1999Jan 23, 2001Edward L. TobinickTNT inhibitors for the treatment of neurological disordersUS6180355 Title not availableUS6201105Jan 20, 1999Mar 13, 2001Craig A. SmithTumor necrosis factor receptor polypeptides recombinant P75 (Type II)US6277966Dec 15, 2000Aug 21, 2001Sumitomochemical Company, Ltd.Azo-compounds and dye polarizing films containing themUS6277969Aug 12, 1998Aug 21, 2001New York UniversityAnti-TNF antibodies and peptides of human tumor necrosis factorUS6284471Feb 4, 1994Sep 4, 2001New York University Medical CenterAnti-TNFa antibodies and assays employing anti-TNFa antibodiesUS6319910Dec 17, 1998Nov 20, 2001Hospital For Joint DiseasesMethod for inhibiting cyclooxygenase-2 and tumor necrosis factor alphaUS6379666Dec 11, 2000Apr 30, 2002Edward L. TobinickTNF inhibitors for the treatment of neurological, retinal and muscular disordersUS6406867Feb 25, 2000Jun 18, 2002Human Genome Sciences, Inc.Antibody to human endokine alpha and methods of useUS6419934Sep 5, 2000Jul 16, 2002Edward L. TobinickTNF modulators for treating neurological disorders associated with viral infectionUS6419944Apr 5, 2001Jul 16, 2002Edward L. TobinickCytokine antagonists for the treatment of localized disordersUS6423321Dec 27, 2000Jul 23, 2002Edward L. TobinickCytokine antagonists for the treatment of sensorineural hearing lossUS6428787Sep 19, 2000Aug 6, 2002Edward L. TobinickTNF inhibitors for the treatment of retinal disordersUS6471961May 2, 2000Oct 29, 2002Edward L. TobinickInterleukin antagonists for the treatment of neurological, retinal and muscular disordersUS6537549Apr 25, 2001Mar 25, 2003Edward L. TobinickCytokine antagonists for the treatment of localized disordersUS6572852Jan 12, 2001Jun 3, 2003Immunex CorporationMethod for suppressing inflammatory responses by administering TNFRUS6623736May 23, 2002Sep 23, 2003Edward L. TobinickInterleukin antagonists for the treatment of neurological, retinal and muscular disordersUS6635250Jan 17, 2001Oct 21, 2003A+ Science Ab (Publ)Use of certain metalloproteinase inhibitors for treating nerve disorders mediated by nucleus pulpsusUS6649589Sep 23, 1999Nov 18, 2003A+ Science Ab (Publ)Use of certain drugs for treating nerve root injuryUS6790444Jan 8, 2001Sep 14, 2004New York University Medical CenterAnti-TNF antibodies and peptides of human necrosis factorUS6835823Jan 8, 2001Dec 28, 2004New York UniversityAnti-TNF antibodies and peptides of human tumor necrosis factorUS6896904Jun 14, 2004May 24, 2005Depuy Spine, Inc.Collagen/polysaccharide bilayer matrixUS6982089Oct 9, 2002Jan 3, 2006Tact Ip, LlcCytokine antagonists for neurological and neuropsychiatric disordersUS6991791Jan 18, 2001Jan 31, 2006New York University School Of MedicineAnti-TNF antibodies and peptides of human tumor necrosis factorUS7070775Jul 18, 2002Jul 4, 2006New York UniversityRecombinant A2-specific TNFα specific antibodiesUS7101674Jul 2, 2001Sep 5, 2006New York UniversityAnti-idiotypic anti-TNF antibodies and related immunoassay methodsUS7115557Aug 22, 2002Oct 3, 2006Sciaticon AbUse of certain drugs for treating nerve root injuryUS7128907Mar 4, 2003Oct 31, 2006Centocor, Inc.Methods of treating crohn's disease with anti-TNF antibodiesUS7128908Jul 12, 2005Oct 31, 2006Centocor, Inc.Methods for treating systemic lupus erythematosus using anti-TNF antibodies and fragments thereofUS7135178Jun 20, 2002Nov 14, 2006Centocor, Inc.Methods of treating disseminated intravascular coagulation using anti-TNF antibodiesUS7135179Jul 13, 2005Nov 14, 2006Centocor, Inc.Methods for treating sarcoidosis using anti-TNF antibodies and fragments thereofUS7138118Dec 8, 2005Nov 21, 2006Centocor, Inc.Methods of treating rheumatoid arthritis with anti-TNF antibodiesUS7160542Jun 29, 2005Jan 9, 2007New York UniversityMethod of treating psoriasis using human anti-TNF antibodies and fragmentsUS7160543Dec 8, 2005Jan 9, 2007New York UniversityMethods of inhibiting TNF-α in patients with Crohn's diseaseUS7160995Jul 22, 2002Jan 9, 2007New York UniversityDNA encoding anti-TNF antibodies and peptidesUS7166284Feb 21, 2003Jan 23, 2007New York UniversityMethods of treating joint inflammation with anti-TNF antibodiesUS7169386Jan 10, 2002Jan 30, 2007New York UniversityMethods of treating inflammation associated with viral infection with anti-TNF antibodiesUS7169388Sep 30, 2004Jan 30, 2007New York UniversityMethods of inhibiting TNFα in patients with cancerUS7179466Jun 28, 2002Feb 20, 2007New York UniversityMethods of treating rheumatoid arthritis by multiple administration of anti-TNF antibodiesUS7179893Apr 7, 2006Feb 20, 2007New York UniversityRecombinant anti-TNF-α antibodiesUS7192584Aug 10, 2001Mar 20, 2007Centocor, Inc.Methods of treating psoriasis with anti-TNF antibodiesUS7204985Feb 21, 2003Apr 17, 2007Centocor, Inc.Methods of treating disseminated intravascular coagulation by multiple administration of anti-TNF antibodiesUS7214376Dec 7, 2001May 8, 2007New York UniversityMethods of inhibiting TNFα in patients with neoplastic diseaseUS7214658Dec 18, 2004May 8, 2007Tact Ip, LlcMethod of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injectionUS7223396Dec 12, 2002May 29, 2007Centocor, Inc.Methods of treatment of fistulas in Crohn's disease with anti-TNF antibodiesUS7226250Dec 22, 2003Jun 5, 2007Hayes Lemmerz International, Inc.Tool and method for forming a lug holeUS7226593Jan 10, 2002Jun 5, 2007Centocor, Inc.Methods of treating cachexia with chimeric anti-TNF antibodiesUS7227003Jun 2, 2005Jun 5, 2007New York UniversityAnti-TNF antibody fragmentsUS7252823Feb 6, 2004Aug 7, 2007Centocor, Inc.Recombinant A2-specific TNFα-specific antibodiesUS7276239Dec 20, 2005Oct 2, 2007Centocor, Inc.Recombinant A2-specific TNFα-specific antibodiesUS7335358Dec 4, 2006Feb 26, 2008Centocor, Inc.Methods of treating psoriasis with anti-TNF antibodiesUS7374761Aug 8, 2007May 20, 2008Centocor, Inc.Recombinant A2-specific TNFα-specific antibodiesUS7404955Aug 2, 2005Jul 29, 2008Centocor, Inc.Methods of inhibiting or neutralizing TNFα in patients with tissue injuryUS7416729Jun 18, 2007Aug 26, 2008Centocor, Inc.Methods of treating rheumatoid arthritis with anti-TNF antibodiesUS7425330Oct 16, 2006Sep 16, 2008Centocor, Inc.Methods of inhibiting TNFα activity in the blood of a patientUS20010027175Jan 17, 2001Oct 4, 2001Kjell OlmarkerUse of certain drugs for treating nerve root injuryUS20010053764May 11, 2001Dec 20, 2001Sims John E.Interleukin-1 inhibitors in the treatment of diseasesUS20010055594Apr 6, 2001Dec 27, 2001Kjell OlmarkerUse of certain drugs for treating nerve root injuryUS20020131954May 23, 2002Sep 19, 2002Tobinick Edward L.Interleukin antagonists for the treatment of neurological, retinal and muscular disordersUS20020132307Jan 8, 2001Sep 19, 2002New York UniversityAnti-TNF antibodies and peptides of human tumor necrosis factorUS20020141996Jan 10, 2002Oct 3, 2002New York University Medical Center and Centocor, Inc.Methods of treating infections with chimeric anti-TNF antibodiesUS20020146419Jan 10, 2002Oct 10, 2002New York University Medical CenterMethods of treating ankylosis with chimeric anti-TNF antibodiesUS20030007972Sep 6, 2002Jan 9, 2003Edward TobinickCytokine antagonists and other biologics for the treatment of bone metastasesUS20030113318Jan 13, 2003Jun 19, 2003Tobinick Edward LewisTNF inhibition for the treatment of pre-menstrual syndrome and primary dysmenorrheaUS20030133935Jul 29, 2002Jul 17, 2003New York UniversityMethods of treating lung pathologies with chimeric anti-TNF antibodiesUS20030147891Aug 23, 2002Aug 7, 2003Centocor, Inc.Anti-TNF antibodies and peptides of human tumor necrosis factorUS20030176332Mar 8, 2002Sep 18, 2003Kjell OlmarkerNovel use of cytokine inhibitorsUS20030180299Jun 28, 2002Sep 25, 2003New York UniversityTreatment of heart pathology with chimeric anti-TNF antibodiesUS20030185826Mar 21, 2003Oct 2, 2003Tobinick Edward L.Cytokine antagonists for the treatment of localized disordersUS20030204066Feb 21, 2003Oct 30, 2003New York UniversityMethods of treating psoriatic arthritis with chimeric anti-TNF antibodiesUS20040115200Sep 19, 2003Jun 17, 2004New York UniversityMethods of treating neurodegenerative inflammation with chimeric anti-TNF antibodiesUS20040120977Dec 10, 2003Jun 24, 2004Dodd John H.Anti-inflammatory coatings for implantable medical devices and devices containing said coatingsUS20040126372Jul 18, 2003Jul 1, 2004Abbott Biotechnology Ltd.Treatment of TNFalpha related disordersUS20040136990Jul 18, 2003Jul 15, 2004Abbott Biotechnology Ltd.Treatment of pain using TNFalpha inhibitorsUSRE36755Aug 31, 1998Jun 27, 2000Immunex CorporationDNA encoding tumor necrosis factor-α and -β receptorsNon-Patent CitationsReference1"Adult low back pain." National Guideline Clearinghouse, [www.guideline.gov], printed 2007.2"Development of Enbrel� (etanercept)," http://www.enbrel.com/rheumatology/enbrel-rhcpabout-devel.jsp, printed Oct. 19, 2005, 2 pages.3"Guidelines for the performance of fusion procedures for degenerative disease of the lumbar spine. Part 10: fusion following decompression in patients with stenosis without spondylolisthesis." National Guideline Clearinghouse, [www.guideline.gov], printed 2007.4"Guidelines for the performance of fusion procedures for degenerative disease of the lumbar spine. Part 13: injection therapies, low-back pain, and lumbar fusion." National Guideline Clearinghouse, [www.guideline.gov], printed 2007.5"Guidelines for the performance of fusion procedures for degenerative disease of the lumbar spine. Part 5: correlation between radiographic and functional outcome." National Guideline Clearinghouse, [www.guideline.gov], printed 2007.6"Guidelines for the performance of fusion procedures for degenerative disease of the lumbar spine. Part 6: magnetic resonance imaging and discography for patient selection for lumbar fusion." National Guideline Clearinghouse, [www.guideline.gov], printed 2007.7"Guidelines for the performance of fusion procedures for degenerative disease of the lumbar spine. Part 7: intractable low-back pain without stenosis or spondylolisthesis." National Guideline Clearinghouse, [www.guideline.gov], printed 2007.8"Guidelines for the performance of fusion procedures for degenerative disease of the lumbar spine. Part 8: lumbar fusion for disc herniation and radiculopathy." National Guideline Clearinghouse, [www.guideline.gov], printed 2007.9"Guidelines for the performance of fusion procedures for degenerative disease of the lumbar spine. Part 9: fusion in patients with stenosis and spondylolisthesis." National Guideline Clearinghouse, [www.guideline.gov], printed 2007.10"Guidelines for the performance of fusion procedures for degenerative disease of the lumbar spine." National Guideline Clearinghouse, [www.guideline.gov], printed 2007.11"Interventional techniques: evidence-based practice guidelines in the management of chronic spinal pain." National Guideline Clearinghouse, [www.guideline.gov], printed 2007.12"Low back pain." National Guideline Clearinghouse, [www.guideline.gov], printed 2007.13"Low back-lumbar & thoratic (acute & chronic)." National Guideline Clearinghouse, [www.guideline.gov], printed 2007.14"Neck and upper back (acute & chronic)." printed 2007 National Guideline Clearinghouse, [www.guideline.gov], printed 2007.15"North American Spine Society Phase III: clinical guidelines for multidisciplinary spine care specialists. Spinal stenosis version 1.0." National Guideline Clearinghouse, [www.guideline.gov], printed 2007.16"The body's own toxoids help in therapy," Dec. 12, 1999, http://www.rp-online.de/news/wissenschaft/1999-1230/bandscheibenvorfall.html, translation included.17"Low back—lumbar & thoratic (acute & chronic)." National Guideline Clearinghouse, [www.guideline.gov], printed 2007.18Amin et al., "A novel mechanism of action of tetracyclines: Effects on nitric oxide synthases," Proc. Natl. Acad. Sci. USA, 1996, 93:14014-14019.19Aoki et al., "Local Application of Disc-Related Cytokines on Spinal Nerve Roots," Spine, 2002, 27(15):1614-1617.20Arai et al., "Indomethacin blocks the nucleus pulposus-induced effects on nerve root function. An experimental study in dogs with assessment of nerve conduction and blood flow following experimental disc herniation," Eur. Spine J., 2004, 13(8):691-694.21Arden et al., "A multicentre randomized controlled trial of epidural corticosteroid injections for sciatica: the WEST study," Rheumatology, 44; pp. 1399-1406, (2005).22Autio et al., "The Effect of Infiximab, a Monoclonal Antibody Against TNF-a, on Disc Herniation Resorption," Spine, 31(23); pp. 2641-2645, (2006).23Baumgartner et al., "Constitutive and Inducible Mechanisms for Synthesis and Release of Cytokines in Immune Cell Lines," J. Immunol., 1996, 157:4087-4093.24Bidani and Heming, "Effects of Lidocaine on Cytosolic pH Regulation and Stimulus-Induced Effector Functions in Alveolar Macrophages," Lung, 1997, 175:349-361.25Black et al., "A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells," Nature, 1997, 385:729-733.26Black et al., "A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells," Nature, 1997, 385:729-733.27Bluth� et al., "Interleukin-1 mediates behavioural but not metabolic effects of tumor necrosis factor alpha in mice," Eur. J. Pharmacol., 1991, 209:281-283.28Bluth� et al., "Interleukin-1 mediates behavioural but not metabolic effects of tumor necrosis factor α in mice," Eur. J. Pharmacol., 1991, 209:281-283.29Boden et al., "Abnormal Magnetic-Resonance Scans of the Lumbar Spine in Asymptomatic Subjects. A prospective investigation," J. Bone Joint Surg., 1990, 72A(3):403-408.30Boos et al., "1995 Volvo Award in Clinical Sciences. The Diagnostic Accuracy of Magnetic Resonance Imaging, Work Perception, and Psychosocial Factors in Identifying Symptomatic Disc Herniations," Spine, 1995, 20(24):2613-2625.31Boos et al., "Tissue Characterization of Symptomatic and Asymptomatic Disc Herniations by Quantitative Magnetic Resonance Imaging," J. Orthop. Res., 1997, 15:141-149.32Bourrie et al., "Enhancement of endotoxin-induced interleukin-10 production by SR 31747A, a sigma ligand," Eur. J. Immunol., 1995, 25:2882-2887.33Brattsand and Linden, "Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies," Aliment Pharmacol. Ther., 1996, 10(suppl 2):81-90.34Brennan et al., "Treating Sciatica with Adalimumab: A Pilot Study," SAT0146, 1 page, 2004.35Brisby et al., "Inflammation in disc herniation may be a response to nucleus pulposus cell cytokine production and not primary infiltration of inflammatory cells," 45th Annual Meeting Orthopaedic Research Society, Feb. 1-4, 1999, Anaheim, CA, 1 page.36Brisby et al., "Proinflammatory cytokines in cerebrospinal fluid and serum in patients with disc herniation and sciatica," Eur. Spine J., 2002, 11:62-66.37Buck and Cooperman, "Single Protein Omission Reconstitution Studies of Tetracycline Binding to the 30S Subunit of Escherichia coli Ribosomes," Biochemistry, 1990, 29(22):5374-5379.38Burke et al., "Intervertebral discs which cause low back pain secrete high levels of proinflammatory mediators," J. Bone Joint Surg. Br., 2002, 84:196-201.39Burke et al., "Spontaneous Production of Monocyte Chemoattractant Protein-1 and Interleukin-8 by the Human Lumbar Intervertebral Disc," Spine, 2002, 27(13):1402-1407.40Buttermann, "Treatment of Lumbar Disc Herniation: Epidural Steroid Injection Compared with Discectony. A Prospective, Randomized Study," JB&JS, p. 670, (2006).41Byr�d et al., "A Rapid Transport Route Between the Epidural Space and the Intraneural Capillaries of the Nerve Roots," Spine, 1995, 20(2):138-143.42Byr�d et al., "Methylprednisolone Reduces the Early Vascular Permeability Increase in Spinal Nerve Roots Induced by Epidural Nucleus Pulposus Application," J. Orthop. Res., 1987, 18:983-987.43Carette et al., "Epidural Corticosteroid Injections for Sciatica Due to Herniated Nucleus Pulposus," New England J. of Med., p. 1634, (1997).44Chao et al., "Interleukin-1 and Tumor Necrosis Factor-alpha Synergistically Mediate Neurotoxicity: Involvement of Nitric Oxide and of N-Methyl-D-aspartate Receptors," Brain Behav. Immun., 1995, 9:355-365.45Chao et al., "Interleukin-1 and Tumor Necrosis Factor-α Synergistically Mediate Neurotoxicity: Involvement of Nitric Oxide and of N-Methyl-D-aspartate Receptors," Brain Behav. Immun., 1995, 9:355-365.46Chapple et al., "Structure-Function Relationship of Antibacterial Synthetic Peptides Homologous to a Helical Surface Region on Human Lactoferrin against Escherichia coli Serotype O111, " Infection and Immunity, 1998, 66(6):2434-244047Chin et al., "Etanercept (Enbrel�) therapy for chronic inflammatory demyelinating polyneuropathy," J. Neurol. Sci., 2003, 210:19-21.48Cohen, "A Double-Blind, Placebo-controlled, Dose-Response Pilot Study Evaluating Intradiscal Etanercept in Patients with Chronic Discogenic Low Back Pain or Lumbosacral Radiculopathy," Anesthesiology, 107, pp. 99-105 (2007).49Cornefjord et al., "Nucleus pulposus-induced nerve root injury: effects of diclofenac and ketoprofen," Eur. Spine J., 2002, 11:57-61.50Crickmore and Salmond, "The Escherichia coli heat shock regulatory gene is immediately downstream of a cell division operon: the fam mutation is allelic with rpoH," Mol. Gen. Genet., 1986, 205:535-539.51Curriculum Vitae of Mark L. Heaney, M.D., Ph.D., Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University Required Format for Curriculum Vitae and Bibliography, May 11, 2009 (11 pages).52Cyteval et al, "Predictive Factors of Efficacy of Periradicular Corticosteroid Injections for Lumbar Radiculopathy," AJNR, 27; p. 978, (2006).53Dawson et al., "Cyclosporin A inhibits the in vivo production of interleukin-1beta and tumour necrosis factor alpha, but not interleukin-6, by a T-cell-independent mechanism," Cytokine, 1996, 8(12):882-888.54Dawson et al., "Cyclosporin A inhibits the in vivo production of interleukin-1β and tumour necrosis factor α, but not interleukin-6, by a T-cell-independent mechanism," Cytokine, 1996, 8(12):882-888.55DeLeo et al., "Cytokine and growth factor immunohistochemical spinal profiles in two animal models of mononeuropathy," Brain Res., 1997, 759:50-57.56Development of ENBREL[www.enbrel.com/hcp/enbrel-development.jsp], printed on Sep. 6, 2009 (3 pages).57Deyo, "Back Surgery-Who Needs It?" Massachusetts Medical Society, p. 2239, (2007).58Deyo, "Back Surgery—Who Needs It?" Massachusetts Medical Society, p. 2239, (2007).59Dhainaut et al., "CDP571, a humanized antibody to human tumor necrosis factor-alpha: Safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock," Crit. Care Med., 1995, 23(9):1461-1469.60Dhainaut et al., "CDP571, a humanized antibody to human tumor necrosis factor-α: Safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock," Crit. Care Med., 1995, 23(9):1461-1469.61Dick et al., "Neutralizing TNF-alpha Activity Modulates T-cell Phenotype and Function in Experimental Autoimmune Uveoretinitis," J. Autoimmunity, 1998, 11(3):255-264.62Enbrel� (etanercept) For Subcutaneous Injection (2 pages), 2000.63Evans, et al., "Protective Effect of 55- but not 75-kD Soluble Tumor Necrosis Factor Receptor-Immunoglobulin G Fusion Proteins in an Animal Model of Gram-negative Sepsis," J. Exp. Med., 1994, 180: 2173-2179.64Finckh et al., "Short-Term Efficacy of Intravenous Pulse Glucocorticoids in Acute Discogenic Sciatica. A Randomized Controlled Trial," Spine, 31(4); pp. 377-381, (2006).65Furst et al., "Intravenous Human Recombinant Tumor Necrosis Factor Receptor p55-Fc IgG1 Fusion Protein, Ro 45/2081 (Lenercept): Results of a Dose-Finding Study in Rheumatoid Arthritis," The J. of Rheumatology, 2003, 30: 2123-2126.66Gadient et al., "Interleukin-1 beta and tumor necrosis factor-alpha synergistically stimulate nerve growth factor (NGF) release from cultured rat astrocytes," Neurosci. Lett., 1990, 117:335-340.67Gadient et al., "Interleukin-1 β and tumor necrosis factor-α synergistically stimulate nerve growth factor (NGF) release from cultured rat astrocytes," Neurosci. Lett., 1990, 117:335-340.68Galley et al, "The immuno-inflammatory cascade," British J. of Anaesthesia, 77; pp. 11-16, (1996).69Garcia-Vicuna et al., "Prevention of cytokine-induced changes in leukocyte adhesion receptors by nonsteroidal antiinflammatory drugs from the oxicam family," Arthritis Rheum., 1997, 40:143-153.70Garcia-Vicuńa et al., "Prevention of cytokine-induced changes in leukocyte adhesion receptors by nonsteroidal antiinflammatory drugs from the oxicam family," Arthritis Rheum., 1997, 40:143-153.71Gearing et al., "Processing of tumour necrosis factor-alpha precursor by metalloproteinases," Nature, 1994, 370:555-557.72Gearing et al., "Processing of tumour necrosis factor-α precursor by metalloproteinases," Nature, 1994, 370:555-557.73Gelderd et al., "The Effects of Interleukin-1 Receptor Antagonist Protein (IRAP) Infusion Following Spinal Cord Transection in Rats," Mol. Chem. Neuropathol., 1996, 27(2):167-183.74Genevay et al., "Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study," Ann. Rheum. Dis., 63; pp. 1120-1123, (2004).75Gill and Salmond, "The identification of the Escherichia coli ftsY gene product: an unusual protein," Mol. Microbiol., 1990, 4(4):575-583.76Gill and Salmond, "The identification of the Escherichia coli ƒtsY gene product: an unusual protein," Mol. Microbiol., 1990, 4(4):575-583.77Goetzl et al., "Matrix Metalloproteinases in Immunity," J. Immunol., 1996, 156:1-4.78Gonzalez et al., "Long-term effect of nonsteroidal anti-inflammatory drugs on the production of cytokines and other inflammatory mediators by blood cells of patients with osteoarthritis," Agents Actions, 1994, 41:171-178.79Goupille, et al., "The Role of Inflammation in Disk Herniation-Associated Radiculopathy," Semin. Arthritis Rheum., 1998, 28(1): 60-71.80Goupille, et al., "The Role of Inflammation in Disk Herniation—Associated Radiculopathy," Semin. Arthritis Rheum., 1998, 28(1): 60-71.81Hartung et al., "Inflammatory mediators in demyelinating disorders of the CNS and PNS," J. Neuroimmunol., 1992, 40:197-210.82Hattori et al., "Tumor necrosis factor is markedly synergistic with interleukin I and interferon-65 in stimulating the production of nerve growth factor in fibroblasts," FEBS Lett., 1994, 340:177-180.83Hattori et al., "Tumor necrosis factor is markedly synergistic with interleukin I and interferon-65 in stimulating the production of nerve growth factor in fibroblasts," FEBS Lett., 1994, 340:177-180.84Herman et al., "Nonsteroidal Antiinflammatory Drug Modulation of Prosthesis Pseudomembrane Induced Bone Resorption," J. Rheumatol., 1994, 21:338-343.85Heyde et al., "Trauma induces apoptosis in human thoracolumbar intervertebral discs," BMC Clinical Path., 6(5); 9 pages, (2006).86Homma et al., "A comparison of chronic pain behavior following local application of tumor necrosis factor alpha to the normal and mechanically compressed lumbar ganglia in the rat," Pain, 2002, 95:239-246.87Homma et al., "A comparison of chronic pain behavior following local application of tumor necrosis factor α to the normal and mechanically compressed lumbar ganglia in the rat," Pain, 2002, 95:239-246.88Igarashi et al., "2000 Volvo Award Winner in Basic Science Studies: Exogenous Tumor Necrosis Factor-Alpha Mimics Nucleus Pulposus-Induced Neuropathology. Molecular, Histologic, and Behavioral Comparisons in Rats," Spine, 2000, 25(23):2975-2980.89Iwabuchi et al., "Effects of Anulus Fibrosus and Experimentally Degenerated Nucleus Pulposus on Nerve Root Conduction Velocity," Spine, 2001, 26(15):1651-1655.90Iwamoto and Takeda, "Possible cytotoxic mechanisms of TNF in vitro," Hum. Cell., 1990, 3:107-112 (English summary attached).91Jeanjean et al., "Interleukin-1beta induces long-term increase of axonally transported opiate receptors and substance P," Neuroscience, 1995, 68(1):151-157.92Jeanjean et al., "Interleukin-1β induces long-term increase of axonally transported opiate receptors and substance P," Neuroscience, 1995, 68(1):151-157.93Jurd et al., "Endothelial cell activation in cutaneous vasculitis," Clin. Exp. Dermatol., 1996, 21:28-32.94Karpinen et al., "Periradicular Infiltration for Scatica," SPINE, 26(9); pp. 1059-1067, (2001).95Karppinen et al., "Treatment of Sciatica with Infliximab, a monoclonal humanised chimaeric antibody against TNF-α," J. Bone Joint Surg., 2004, 86B(suppl 3):341-342, Abstract O3057.96Karppinen et al., "Tumor Necrosis Factor-α Monoclonal Antibody, Infliximab, Used to Manage Severe Sciatica," Spine, 2003, 28(8):750-754.97Kawakami et al., "mRNA Expression of Interleukins, Phospholipase A2, and Nitric Oxide Synthase in the Nerve Root and Dorsal Root Ganglion Induced by Autologous Nucleus Pulposus in the Rat," J. Orthopaedic Res., 1999, 17:941-946.98Kawakami et al., "Pathomechanism of Pain-Related Behavior Produced by Allografts of Intervertebral Disc in the Rat," Spine, 1996, 21(18):2101-2107.99Kayama et al., "Cultured, Autologous Nucleus Pulposus Cells Induce Functional Changes in Spinal Nerve Roots," Spine, 1998, 23(20):2155-2158.100Kayama et al., "Incision of the Anulus Fibrosus Induces Nerve Root Morphologic, Vascular, and Functional Changes. An experimental study," Spine, 1996, 21(22):2539-2543.101Kloppenburg et al., "The influence of tetracyclines on T cell activation," Clin. Exp. Immunol., 1995, 102:635-641.102Kloppenburg et al., "The Tetracycline Derivative Minocycline Differentially Affects Cytokine Production by Monocytes and T Lymphocytes," Antimicrob. Agents Chemother., 1996, 40(4):934-940.103Klusman and Schwab, "Effects of pro-inflammatory cytokines in experimental spinal cord injury," Brain Res., 1997, 762:173-184.104K�ller et al., "Immunologically induced electrophysiological dysfunction: Implications for inflammatory diseases of the CNS and PNS," Prog. Neurobiol., 1997, 52:1-26.105Korhonen et al, "Efficacy of Infiximab for Disc Herniation-Induced Sciatica," SPINE, 29(19); pp.2115-2119, (2004).106Korhonen et al, "The Efficacy of Infliximab for Disc Herniation-Induced Sciatica. A 1-Year Follow-Up of FIRST II, A Randomised Controlled Trial," 1 page, 2004.107Korhonen, "The Treatment of Disc Herniation-Induced Sciatica With Infliximab," SPINE, (31):24, pp. 2759-2766, (2006).108Korner et al, "Critical Points of Tumor Necrosis Factor Action in Central Nervous System Autoimmune Inflammation Defined by Gene Targeting," J. Exp. Med., 186(9); pp. 1585-1590, (1997).109Kraemer et al., "Lumbar epidural perineural injection: a new technique," Eur. Spine J., 1997,6(5):357-361.110Krakauer et al., "Doxycycline Is Anti-Inflammatory and Inhibits Staphylococcal Exotoxin-Induced Cytokines and Chemokines," Antimicrob. Agents and Chemotherapy, Nov. 2003, vol. 47(11): pp. 3630-3633.111Lamster et al., "The effect of tetracycline fiber therapy on β-glucuronidase and interleukin-1β in crevicular fluid," J. Clin. Periodontol., 1996, 23:816-822.112Liberski et al., "Further ultrastructural studies of lesions induced in the optic nerve by Tumor necrosis factor alpha (TNF-α): a comparison with experimental Creutzfeldt-Jakob disease," Acta Neurobiol. Exp., 1994, 54:209-218.113Lin et al, "Cervical Epidural Steroid Injections for Symptomatic Disc Herniations," J. Spinal Disord. Tech., 19(3); p. 183, (2005).114Lin et al., "An immunohistochemical study of TNF-α in optic nerves from AIDS patients," Curr. Eye Res., 1997, 16:1064-1068.115Liu et al., "Increased Sensitivity of Sensory Neurons to Tumor Necrosis Factor α in Rats with Chronic Compression of the Lumbar Ganglia," J. Neurophysiol., 2002, 88:1393-1399.116Lorenz and Kalden, "Biological Agents in Rheumatoid Arthritis," BioDrugs, 1998, 9(4):303-324.117Lundin, "Corticosteroids in Lumbar Disc Surgery," Eur. Spine J., 12; pp. 625-630, (2003).118Madigan et al., "Tumor necrosis factor-alpha (TNF-α)-induced optic neuropathy in rabbits," Neurol. Res., 1996, 18:176-184.119Malcangio et al., "Effect of interleukin-1βon the release of substance P from rat isolated spinal cord," Eur. J. Pharmacol., 1996, 299:113-118.120Matsumori et al., "Amiodarone Inhibits Production of Tumor Necrosis Factor-αby Human Mononuclear Cells. A Possible Mechanism for its Effect in Heart Failure," Circulation, 1997, 96:1386-1389.121Milano et al., "Intraperitoneal Injection of Tetracyclines Protects Mice from Lethal Endotoxemia Downregulating Inducible Nitric Oxide Synthase in Various Organs and Cytokine and Nitrate Secretion in Blood," Antimicrob. Agents Chemother., 1997, 41:117-121.122Mixter and Barr, "Rupture of the intervertebral disc with involvement of the spinal canal," New Eng. Surg. Soc., 1934, 211(6):210-215.123Moelling, "DNA for genetic vaccination and therapy," Cytokines Cell. Mol. Ther., 1997, 3(2):127-136.124Mohler et al., "Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists," J. Immunol., 1993, 151(3); pp. 1548-1561.125Muto et al., "Treatment of Herniated Lumbar Disc by Intradiscal and Intraforaminal Oxygen-Ozone (O2-O3) Injection," J. Neuroradiol., 2004, 31; pp. 183-189.126Muto, "Intradiscal-Intraforaminal Oxygen-Ozone Therapy in the Treatment of Low Back Pain and Sciatica," Cardarelli Hospital, pp. 117-119, 2004.127Nawroth et al., "Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas," J. Exp. Med., 1988, 168:637-647.128Nishi et al., "DNA Sequence and Complementation Analysis of a Mutation in the rplX Gene from Escherichia coli Leading to Loss of Ribosomal Protein L24," J. Bacteriol., 1985, 163(3):890-894.129Notice of Allowance mailed Oct. 30, 2009; Canada Patent Application No. 2,342,200.130Odell et al., "Antibacterial activity of peptides homologous to a loop region in human lactoferrin," FEBS Lett., 1996, 382:175-178.131Office Action mailed Aug. 3, 2009; EP Application No. 07009705.0.132Office Action mailed Nov. 20, 2009; Japan Application No. 2000-571927.133Ohtori et al, "Tumor Necrosis Factor-Immunoreactive Cells and PGP 9.5-Immunoreactive Nerve Fibers in Vertebral Endplates of Patients with Discogenic Low Back Pain and Modic Type 1 or Type 2 Changes on MRI," Spine, 31(9); pp. 1026-1031, (2006).134Oka et al., "Intracerebroventricular Injection of Tumor Necrosis Factor-α Induces Thermal Hyperalgesia in Rats," Neuroimmunomodulation, 1996, 3:135-140.135Olmarker and Larsson, "Tumor Necrosis Factor α and Nucleus-Pulposus-Induced Nerve Root Injury," Spine, 1998, 23(23): 2538-2544.136Olmarker and Myers, "Pathogenesis of sciatic pain: role of herniated nucleus pulposus and deformation of spinal nerve root and dorsal root ganglion," Pain, 1998, 78(2):99-105.137Olmarker and Rydevik, "Selective Inhibition of Tumor Necrosis Factor-α Prevents Nucleus Pulposus-Induced Thrombus Formation, Intraneural Edema, and Reduction of Nerve Conduction Velocity. Possible Implications for Future Pharmacologic Treatment Strategies of Sciatica," Spine, 2001, 26(8):863-869.138Olmarker et al., "Autologous Nucleus Pulposus Induces Neurophysiologic and Histologic Changes in Porcine Cauda Equina Nerve Roots," Spine, 1993, 18(11):1425-1432.139Olmarker et al., "Effects of Methylprednisolone on Nucleus Pulposus-Induced Nerve Root Injury," Spine, 1994, 19(16):1803-1808.140Olmarker et al., "Inflammatogenic Properties of Nucleus Pulposus," Spine, 1995, 20(6):665-669.141Olmarker et al., "The Effects of Normal, Frozen, and Hyaluronidase-Digested Nucleus Pulposus on Nerve Root Structure and Function," Spine, 1997, 22(5):471-476.142Olmarker et al., "Ultrastructural Changes in Spinal Nerve Roots Induced by Autologous Nucleus Pulposus," Spine, 1996, 21(4):411-414.143Olmarker, et al., "Tumor Necrosis Factor α and Nucleus-Pulposus-Induced Nerve Root Injury," Spine, 1998, 23(23): 2538-2544.144Olmarker, Summary of U.S. Appl. No. 09/760,811, filed Jan. 17, 2001 (10 pages).145Onda et al., "Exogenous Tumor Necrosis Factor-α Induces Abnormal Discharges in Rat Dorsal Horn Neurons," Spine, 2002, 27(15):1618-1624.146Onrust, et al "Infiximab: A Review of its Use in Crohn's Disease and Rheumatoid Arthritis," BioDrugs, 1998, 10(5): 397-422.147Otani et al., "Nucleus Pulposus-induced Nerve Root Injury: Relationship between Blood Flow and Motor Nerve Conduction Velocity," Neurosurgery, 1999, 45(3):614-620.148Pennica et al., "Cardiotrophin-1, a Cytokine Present in Embryonic Muscle, Supports Long-Term Survival of Spinal Motoneurons," Neuron, 1996, 17:63-74.149Person, "Dermatomyositis responding to pentoxifylline," Br. J. Dermatol., 1995, 134(3):593.150Petrovich et al., "Pentoxifylline suppression of TNF-α mediated axonal degeneration in the rabbit optic nerve," Neurol. Res., 1997, 19:551-554.151Pichler et al., "High IL-5 Production by Human Drug-Specific T Cell Clones," Int. Arch. Allergy Immunol., 1997, 113:177-180.152Plata-Salaman et al., "Interleukin-1β enhances spinal cord blood flow after intrathecal administration in the normal rat," Am. J. Physiol., 1995, 269:R1032-R1037.153Rand et al., "Murine Nucleus Pulposus-Derived Cells Secrete Interleukins-1-β-6, and -10 and , Granulocyte-Macrophage Colony-Stimulating Factor in Cell Culture," Spine, 1997, 22(22):2598-2601.154Raoul et al., "Chronic activation in presymptomatic amyotrophic lateral sclerosis (ALS) mice of a feedback loop involving Fas, Daxx, and FasL," PNAS, 103(15); pp. 6007-6012, (2006).155Redford et al., "Vascular changes and demyelination induced by the intraneural injection of tumour necrosis factor," Brain, 1995, 118:869-878.156Reinecke et al., "In vitro Transfer of Genes into Spinal Tissues," Z. Orthop., 1997, 135(5):412-416 (English summary included).157Reinecke et al., "The Use of Interleukin-1-Receptor Antagonist (IL-1 ra) in the Treatment of the Lumbar Facet Syndrome," ISSLS, Abstracts 2000, Adelaide, Australia, Abstract 173.158Riew et al, "Nerve Root Blocks in the Treatment of Lumbar Radicular Pain. A Minimum Five-Year Follow-Up," JB&JS, 82(11); p. 1722, (2006).159Riew et al, "The Effect of Nerve-Root Injections on the Need for Operative Treatment of Lumbar Radicular Pain: A Prospective, Randomized, Controlled, Double-Blind Study," JB&JS, p. 1589, (2000).160Robache-Gallea et al., "Partial purification and characterization of a tumor necrosis factor-α converting activity," Eur. J. Immunol., 1997, 27:1275-1282.161Rosendahl et al., "Identification and Characterization of a Pro-tumor Necrosis Factor-α-processing Enzyme from the ADAM Family of Zinc Metalloproteases," J. Biol. Chem., 1997, 272(39):24588-24593.162Rost, "Twilight zone of protein sequence alignments," Protein Engineering, 1999, 12(2):85-94.163Rowin et al., "Etanercept treatment in corticosteroid-dependent myasthenia gravis," Neurology, 2004, 63:2390-2392.164Rydevik et al., "Effects of graded compression and nucleus pulposus on nerve tissue: an experimental study in rabbits," Acta Orthop. Scand., 1983, 54:670-671.165Safieh-Garabedian et al., "Contribution of interleukin-1β to the inflammation-induced increase in nerve growth factor levels and inflammatory hyperalgesia," Brit. J. Pharmacol., 1995, 115(7):1265-1275.166Safieh-Garabedian et al., "Involvement of Interleukin-1β, Nerve Growth Factor, and Prostaglandin-E2 in the Hyperalgesia Induced by Intraplantar Injections of Low Doses of Thymulin," Brain Behav. Immun., 1997, 11(3):185-200.167Safieh-Garabedian et al., "Zinc Reduces the Hyperalgesia and Upregulation of NGF and IL-1β Produced by Peripheral Inflammation in the Rat," Neuropharmacol., 1996, 35(5):599-603.168Said and Hontebeyrie-Joskowicz, "Nerve lesions induced by macrophage activation," Res. Immunol., 1992, 143:589-599.169Scallon, et al, "Functional Comparisons of Different Tumour Necrosis Factor Receptor/IgG Fusion Proteins," Cytokine, 1995, 7(8), pp. 759-770.170Scallon, et al., "Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists," The Journal of Pharmcology and Experimental Therapeutics, 2002, 301(2); pp. 418-426.171Sch�fers et al., "Combined epineurial therapy with neutralizing antibodies to tumor necrosis factor-alpha and interleukin-1 receptor has an additive effect in reducing neuropathic pain in mice," Neurosci. Left., 2001, 310:113-116.172Schenk and Reiter, "Intrathecal cortison injection in lumbar disc problems," Arch. Orthopadische Und Unfall-Chirurgie, 1976, 85(1):21-31 (English abstract).173Schlumpf and Johr, "Acute lumbar disk displacement with nerve root compression. Indications for peridural steroid injection," Schweizerische Rundschau Fur Medizin Praxis, 1997, 86(8):292-295.174Seekamp et al., "Requirements for tumor necrosis factor-alpha and interleukin-1 in limb ischemia/reperfusion injury and associated lung injury," Am. J. Pathol., 1993, 143(2):453-463.175Sekut et al., "AntiTNF-agents in the treatment of inflammation," Exp Opin Invest Drugs, 1998, 7(11):1825-1839.176Selmaj and Raine, "Tumor Necrosis Factor Mediates Myelin and Oligodendrocyte Damage In Vitro," Ann. Neurol., 1988, 23:339-346.177Shapira et al., "Human Monocyte Response to Cementum Extracts From Periodontally Diseased Teeth: Effect of Conditioning With Tetracycline," J. Periodontol., 1996, 67:682-687.178Shapira et al., "Tetracycline inhibits Porphyromonas gingivalis lipopolysaccharide-induced lesions in vivo and TNFα processing in vitro," J. Periodont. Res., 1997, 32:183-188.179Sharief et al., "Circulating Tumor Necrosis Factor-α Correlates with Electrodiagnostic Abnormalities in Guillain-Barr� Syndrome," Ann. Neurol., 1997, 42:68-73.180Sharma et al., "Topical application of TNF-α antiserum attenuates spinal cord trauma induced edema formation, microvascular permeability disturbances and cell injury in the rat," Acta Neurochir, 2003, 86(suppl):1-7.181Shinmei et al., "The Role of Interleukin-1 on Proteoglycan Metabolism of Rabbit Annulus Fibrosus Cells Cultured In Vitro," Spine, 1988, 13(11):1284-1290.182Skouen et al., "Protein Markers in Cerebrospinal Fluid in Experimental Nerve Root Injury. A study of slow-onset chronic compression effects or the biochemical effects of nucleus pulposus on sacral nerve roots," Spine, 1999, 24(21):2195-2200.183Smith et al., "Cyclosporin A blocks induction of tumor necrosis factor-alpha in human B lymphocytes," Biochem. Biophys. Res. Commun., 1994, 204:383-390.184Smith, "Microbial pathogen genomes-new strategies for identifying therapeutics and vaccine targets," Tibtech, 1996, 14:290-293.185Smolen et al., "Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomized, multicentre trial," Lancet, 1999, 353:259-266.186Sommer et al., "A metalloprotease-inhibitor reduces pain associated behavior in mice with experimental neuropathy," Neurosci. Letters, 1997, 237:45-48.187Sommer et al., "Etanercept reduces hyperalgesia in experimental painful neuropathy," J. Peripheral Nerve Syst., 2001, 6:67-72.188Sommer et al., "The effect of thalidomide treatment on vascular pathology and hyperalgesia caused by chronic constriction injury of rat nerve," Pain, 1998, 74:83-91.189Sorbera, "Etanercept, Antiarthritic TNF-α Antagonist," Drugs of the Future, 1998, 23(9): 951-954.190Sorkin et al., "Tumour necrosis factor-α induces ectopic activity in nociceptive primary afferent fibres," Neuroscience, 1997, 81:255-262.191Steinmeyer et al., "Pharmacological Effect of Tetracyclines on Proteoglycanases from Interleukin-1-Treated Articular Cartilage," Biochem. Pharmacol., 1998, 55:93-100.192Stephens and Shapiro, "Bacterial protein secretion-a target for new antibiotics?" Chem. Biol., 1997, 4(9):637-641.193Stoll et al., "Tumor necrosis factor-α in immune-mediated demyelination and Wallerian degeneration of the rat peripheral nervous system," J. Neuroimmunol., 1993, 45:175-182.194Szlosarek and Balkwill, "Tumour necrosis factor α: a potential target for the therapy of solid tumours," Lancet Oncol., 2003, 4:565-573.195Takahashi et al., "Inflammatory Cytokines in the Herniated Disc of the Lumbar Spine," Spine, 1996, 21(2):218-224.196Takao et al., "Lidocaine attenuates hyperoxic lung injury in rabbits," Acta Anaesthesiol. Scand., 1996, 40:318-325.197Tartaglia, et al., "The two different receptors for tumor necrosis factor mediate distinct cellular responses," Proc. Natl. Acad. Sci, 1991, vol. 88, pp. 9292-9296.198Teoh et al., "Steroid Inhibition of Cytokine-Mediated Vasodilation After Warm Heart Surgery," Circulation, 1995, 92(suppl 2):II-347-II-353.199The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group, "TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study," Neurology, 1999, 53(3): 457-465.200Tobinick and Davoodifar, "Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients," Curr. Med. Res. Opin., 2004, 20(7):1075-1085.201Tobinick and Davoodifar, "Perispinal TNF-alpha inhibition for discogenic pain," Swiss Med. Wkly., 2003, 133:170-177.202Tobinick, "Targeted Etancercpt for Treatment-Refractory Pain Due to Bone Metastasis: Two Case Reports," Clin. Thera., 2003, 25(8):2279-2288.203Tobinick, "Targeted Etanercept for Discogenic Neck Pain: Uncontrolled, Open-Label Results in Two Adults," Clin. Ther., 2003, 25:1211-1218.204Tracey, et al., "Tumor necrosis factor antagonist mechanisms of action: A comprehensive review," Pharmacology & Therapeutics, 2008, vol. 117; pp. 244-279.205Tsukamoto et al., "Suppressive effects of TNF-α on myelin formation in vitro," Acta Neurol. Scand., 1995, 91:71-75.206U.S. Appl. No. 07/670,827, filed Mar. 18, 1991, Le et al.207U.S. Appl. No. 07/853,606, filed Mar. 18, 1992, Le et al.208U.S. Appl. No. 07/943,852, filed Sep. 11, 1992, Le et al.209U.S. Appl. No. 08/010,406, filed Jan. 29, 1993, Scallon et al.210U.S. Appl. No. 08/013,413, filed Feb. 2, 1993, Le et al.211U.S. Appl. No. 08/442,133, filed May 16, 1995, Scallon et al.212U.S. Appl. No. 08/570,674, filed Dec. 11, 1995, Le et al.213U.S. Appl. No. 09/256,388, filed Feb. 24, 1999, Tobinick214U.S. Appl. No. 09/765,978, filed Jan. 18, 2001, Le et al.215U.S. Appl. No. 09/766,536, filed Jan. 18, 2001, Le et al.216U.S. Appl. No. 09/980,784, filed Jan. 8, 2002, Olmarker et al.217U.S. Appl. No. 10/043,450, filed Jan. 10, 2002, Le et al.218U.S. Appl. No. 10/957,543, filed Sep. 30, 2004, Le et al.219U.S. Appl. No. 11/788,651, filed Apr. 20, 2007, Olmarker et al.220U.S. Appl. No. 12/344,437, filed Dec. 26, 2008, Tobinick et al.221U.S. Appl. No. 12/344,452, filed Dec. 26, 2008, Tobinick.222U.S. Appl. No. 12/346,737, filed Dec. 30, 2008, Tobinick.223U.S. Appl. No. 60/585,735, filed Jul. 6, 2004, Tobinick.224U.S. Appl. No. 60/738,331, filed Nov. 18, 2005, Tobinick.225U.S. Appl. No. 60/760,236, filed Jan. 18, 2006, Tobinick.226van der Poll et al., "Tumor Necrosis Factor-α Induces Activation of Coagulation and Fibrinolysis in Baboons Through an Exclusive Effect on the p55 Receptor," Blood, 1996, 88(3):922-927.227Villarroya et al., "Myelin-induced experimental allergic encephalomyelitis in Lewis rats: tumor necrosis factor α levels in serum of cerebrospinal fluid Immunohistochemical expression in glial cells and macrophages of optic nerve and spinal cord," J. Neuroimmunol., 1996, 64:55-61.228Wacnik et al., "Nociceptive Characteristics of Tumor Necrosis Factor-α in Na�ve and Tumor-Bearing Mice," Neuroscience, 2005, 132:479-491.229Wagner and Myers, "Endoneurial injection of TNF-α produces neuropathic pain behaviors," NeuroReport, 1996, 7:2897-2901.230Wagner and Myers, "Schwann cells produce tumor necrosis factor alpha: expression in injured non-injured nerves," Neuroscience, 1996, 73(3):625-629.231Waki et al., "Preventive effect of cyclosporin A on experimentally induced acute liver injury in as rats," Liver, 1997, 17:107-114.232Wang et al., "Production of tumor necrosis factor in spinal cord following traumatic injury in rats," J. Neuroimmunol., 1996, 69:151-156.233Wehling et al., "Epidural Injections with Interleukin-1-Receptor-Antagonist-Protein (IRAP) in Lumbar Radicular Compression: Pathophysiological Background, Safety and Clinical Results," Int. Soc. Study Lumbar Spine, 1998, p. 16.234Wehling et al., "Neurophysiologic Changes in Lumbar Nerve Root Inflammation in the Rat After Treatment with Cytokine Inhibitors: Evidence for a Role of Interleukin-1," Spine, 1996, 21(8):931-935.235Wehling et al., "The Effect of Cytokines on Regeneration of Compressed Nerve Roots and Transsected Peripheral Nerves," Z. Orthop., 1993, 131:83-93 (English summary included).236Wehling et al., "The interaction between synovial cytokines and peripheral nerve function: a possible element in the development of radicular syndromes," Z. Orthop., 1990, 128(5):442-446 (English summary included).237Wehling et al., "Transfer of Genes to Chondrocytic Cells of the Lumbar Spine: Proposal for a Treatment Strategy of Spinal Disorders by Local Gene Therapy," Spine, 1997, 22(10):1092-1097.238Wehling et al., Information Orthokin, "Die behandlung von eshias, arthrose und rheumatoider arthrisis mit orthokin�," Wissenschaftliche Informationen (Patient Information Paper), relevant portions translated, 2004.239Wehling, "Antizytokine gegen entzundung und schmerz (Anticytokines against inflamation and pain)," Orthopadische Nachrichten, 1998, p. 16, Biermann Verlag GmbH, Koln, Germany, http://www.arthrose-ischias.de/ftp/presse 2.pdf, translation included.240Wehling, "The Use of Cytokine Antagonists in the Treatment of Lumbar Radicular Compression: Pathophysiological Background, Safety and 3 Year Clinical Experience," Abstr. Int. Soc. Study Lumbar Spine, Adelaide, Australia, Apr. 9-13, 2000, Abstract 38.241Wehling, Wissenschaftliches programm (Scientific Program), Jun. 18, 1999, "Epidural injection with a new autologous interleukin-1 receptor-antagonist-protein (IL-1 ra) at radicular compression: pathophysiology, safety and clinical results," http://medweb.uni-muenster.de/institute/orth/versanstaltungen/99-06-18v.html, relevant portions translated.242Weilbach and Gold, "Disease Modifying Treatments for Multiple Sclerosis. What Is On The Horizon?" CNS Drugs, 1999, 11(2):133-157.243Weinblatt et al., "A trial of Etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate," N. Engl. J. Med., 1999, 340(4):253-259.244Weithmann et al., "Effects of tiaprofenic acid on urinary pyridinium crosslinks in adjuvant arthritic rats: Comparison with doxycycline," Inflamm. Res., 1997, 46: 246-252.245Wershil et al., "Dexamethasone Cyclosporin A Suppress Mast Cell-Leukocyte Cytokine Cascades by Multiple Mechanisms," Int. Arch. Allergy Immunol., 1995, 107:323-324.246Wiesel et al., "1984 Volvo Award in Clinical Sciences. A Study of Computer-Assisted Tomography. I. The Incidence of Positive CAT Scans in an Asymptomatic Group of Patients," Spine, 1984, 9(6):549-551.247Willison and Tissot, "The Escherichia coli efg Gene and the Rhodobacter capsulatus adgA Gene Code for NH3-Dependent NAD Synthetase," J. Bacteriol., 1994, 176(11):3400-3402.248Woolf et al., "Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor α," Br. J. Pharmacol., 1997, 121(3):417-424.249Wower et al., "Ribosomal Protein L27 Participates in both 50 S Subunit Assembly and the Peptidyl Transferase Reaction," J. Biol. Chem., 1998, 273(31):19847-19852.250Yabuki et al., "Effects of Lidocaine on Nucleus Pulposus-Induced Nerve Root Injury," Spine, 1998, 23(22):2383-2390.251Yabuuchi et al., "Biphasic effects of intra intracerebroventricular interleukin-1 β on mechanical nociception in the rat," Eur. J. Pharmacol., 1996, 300:59-65.252Zanella et al., "Effect of Etanercept, a Tumor Necrosis Factor-Alpha Inhibitor, on Neuropathic Pain in the Rat Chronic Constriction Injury Model," Spine, 2008, 33(3):227-234.253Zhu et al., "Cytokine Dichotomy in Peripheral Nervous System Influences the Outcome of Experimental Allergic Neuritis: Dynamics of nRNA Expression for IL-1β, IL-6, IL-10, IL-12, TNF-α, TNF-β, and Cytolysin," Clin. Immunol. Immunopathol., 1997, 84:85-94.Classifications U.S. Classification424/130.1, 530/387.1, 424/133.1, 424/145.1, 530/388.23, 424/138.1, 424/135.1, 424/141.1, 530/388.1International ClassificationA61K39/00, A61K39/395, C07K16/24, A61K31/65, C07K16/28, A61K38/17, A61K31/00Cooperative ClassificationC07K16/245, C07K16/241, C07K2317/24, C07K16/2875, A61K38/40, A61K38/20, C07K2316/96, A61K2039/505, A61K31/444, A61K31/00, A61K31/4045, A61K31/65, A61K31/454, A61K38/1793, A61K31/496, A61K2039/507, A61K31/5383, A61K31/501European ClassificationC07K16/24B, C07K16/24F1, A61K31/496, A61K31/65, A61K31/5383, A61K38/17C, C07K16/28Q, A61K31/501, A61K31/00, A61K31/454, A61K31/4045, A61K31/444Legal EventsDateCodeEventDescriptionDec 28, 2010ASAssignmentOwner name: SCIATICON AB, SWEDENFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:OLMARKER, KJELL;RYDEVIK, BJORN;REEL/FRAME:025540/0884Effective date: 20081007Jun 26, 2015REMIMaintenance fee reminder mailedRotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services